Net Margin: 89bio Corp (ETNB)

Graphic logo of 89bio Inc (ETNB)

89bio, Inc. focuses on R&D, outsourcing molecule synthesis and testing to external contractors. Net profit margin reflects this outsourcing strategy, with its latest reading at 0.00. Supply chain continuity is ensured through diversified cold chains, while commercial success depends on the willingness of insurance companies to cover steatohepatitis therapy.

89bio, Inc. (ETNB) Return on Sales by Net Profit: for the period 07/04/2022 - 11/15/2025

Financial and market metric breakdowns for 89bio Corp (ETNB)

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Analysis of all company metrics:89bio, Inc.
Flagship merchandise of 89bio Inc

89bio, Inc. (ETNB) focuses on R&D while fully outsourcing production, shifting financial pressure to external vendors and making operational cost control a critical survival factor. By analyzing the net profit margin, an investor can see the portion of net income in every dollar of revenue, where any upward trend confirms the efficiency of managing costs related to molecule synthesis and clinical trials.